• Price (USD)7.39
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-11.18%
  • Beta--
Data delayed at least 15 minutes, as of Mar 17 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Elekta publ AB is a Sweden-based human care company that develops and sells clinical solutions for the treatment of cancer and brain disorder. The Company offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. The Company has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which creates clinical solutions for radiation therapy, such as linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in the treatment of cancer through internal radiation, and Elekta Software, which develops software solutions for patient information, workflow management and treatment planning in oncology. The Company owns the service business of Asesores Electronicos Especializados SA de CV (AEESA).

  • Revenue in SEK (TTM)15.98bn
  • Net income in SEK813.00m
  • Incorporated1972
  • Employees4.61k
  • Location
    Elekta AB (publ)Kungstensgatan 18STOCKHOLM 113 57SwedenSWE
  • Phone+46 858725400
  • Fax+46 858725500
  • Websitehttps://www.elekta.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
EKTA B:STO since
Premier Business Inter Co Ltd-Solution And Service DistributorAnnounced13 Feb 202313 Feb 2023Announced6.10%--
Data delayed at least 15 minutes, as of Mar 27 2023 15:42 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.